ArticleACS omega2026
Neomycin and Clotrimazole Loaded Chitosan-Based Electrospun Wound Dressing: Development, Characterization, and Antimicrobial Properties.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports a novel approach to chronic wound therapy by fabricating a dual antimicrobial electrospun wound dressing that simultaneously delivers neomycin (antibacterial) and clotrimazole (antifungal) in a poly-(vinyl alcohol) (PVA) and biocompatible chitosan (CS) PVA/CS matrix. Compared to single-drug products in use today, this new dressing mitigates polymicrobial infections characteristic of chronic wounds through controlled dual-drug release kinetics, with initial rapid neomycin (NM) release to instantaneously control bacteria and slow diffusion of clotrimazole (CZ) to provide extended antifungal coverage. Because they take longer to heal, chronic wounds with bacterial and fungal infections pose serious healthcare difficulties. The optimal polymer combination of 3% (w/v) PVA and 3% (w/v) chitosan in a ratio of 4:1 (PVA/CS) was determined, with drug concentrations being 0.5% (w/v) neomycin and 1% (w/v) clotrimazole, and nanofibers with average diameters of 60 ± 18 nm (control) and 87 ± 26 nm (drug-loaded films) were achieved. The dressings reported good mechanical properties (7.49 MPa tensile strength) and enhanced fluid absorption capacities (299% water absorption), suitable for application in wound healing. Kinetic patterns in drug release investigations revealed therapeutic activity optimized uniquely. Neomycin displayed rapid initial release (40% within the first hour) following non-Fickian Weibull kinetics (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.